Advanced Veterinary Biologics Powered by Polymersome Technology

Next-Generation Solutions for Animal Health

AAVACC develops innovative veterinary biologics, including immunostimulants, targeted immunomodulators, and next-generation vaccines, driven by our proprietary polymersome (Artificial Cell Membrane, ACM) delivery platform. Our technology enables targeted antigen delivery, powerful immune activation, and practical application in modern livestock production.

Whether you’re exploring new animal-health technologies, seeking co-development partners, or evaluating platform-based veterinary biologics — AAVACC is ready to collaborate.

Interested in partnering?

About AAVACC

Advancing Veterinary Medicine Through Synthetic Biology

AAVACC Pte Ltd is a Singapore-based biotech company focused on developing novel vaccines for animal health using ACM polymersome technology licensed from ACM Biolabs Pte Ltd

Our mission is simple:

Bring advanced antigen delivery science to livestock vaccines that protect herds, improve performance, and support sustainable farming.

Founded in 2017, AAVACC combines deep scientific expertise with industry experience to develop vaccines that address some of the most economically impactful diseases in pigs, poultry and other livestock.

What We Offer

Technology – Artificial Cell Membranes (ACMs)

A Powerful Delivery Platform for Modern Veterinary Vaccines

Our vaccines use Artificial Cell Membranes (ACMs) — nanoscale polymersome vesicles that mimic biological membranes while offering superior stability and flexibility.

How ACM Technology Works

ACM vesicles are smart, synthetic carriers that can protect and deliver a wide range of biomolecules and drug molecules — from proteins and peptides to DNA, mRNA and oligonucleotides (ODN).

Their polymersome structure keeps these molecules stable and guides them exactly where they need to go, enabling targeted, efficient biological responses.

In short: ACM technology turns delicate molecules into powerful veterinary solutions.

Key Benefits for Animal Health

Robust Antigen Presentation

Stabilized, correctly folded membrane proteins presented in an optimal immune-recognition format.

Strong B- and T-Cell Responses

Supports both humoral and cell-mediated immunity — critical for many challenging pathogens.

High Stability & Scalable Manufacturing

Synthetic polymers offer enhanced physical stability and compatibility with industrial-scale production.

Injectable or Oral Delivery Options

Versatility that allows practical, field-friendly vaccination strategies.

Want to learn how ACM technology can enhance your vaccine pipeline?

Pipeline & Partnerships

Developing Vaccines for High-Impact Livestock Diseases

AAVACC is advancing a pipeline of vaccine candidates targeting economically significant viral and bacterial diseases in livestock.

Our ACM technology has demonstrated safety, immunogenicity, and flexibility, making it an attractive platform for next-generation veterinary vaccines.

Current Focus Areas

Partner With Us

AAVACC actively collaborates with animal health companies to accelerate development and expand access to our ACM technology.

Let’s discuss potential partnerships — schedule a call with us.

We offer:

Partners

Technology Origin – ACM Biolabs Pte Ltd

Our platform is built on the proprietary polymersome technology developed by ACM Biolabs, an internationally recognized leader in synthetic membrane science. AAVACC is the dedicated partner for applying this technology to veterinary applications.

Strategic Investors & Collaborators

AAVACC works with high-level strategic investors who support scalable and sustainable growth in the global animal health market. These partnerships strengthen our scientific roadmap and ensure alignment with real-world industry needs.

Looking to invest or collaborate on novel vaccine technologies?

The People Behind the Science

AAVACC’s leadership blends materials science, immunology, and agricultural industry expertise.

Inventor of the ACM core intellectual property, with extensive research experience across Europe and Singapore.

International entrepreneur and founder of the Erber Group, bringing strategic direction and industry insight.

Responsible for translating ACM platform capabilities into veterinary vaccine products.

Laboratory and experimental specialist supporting assays, analytics and development work.

Media or partner enquiries about our leadership? Reach out to our office.

Join AAVACC

Although we are not actively hiring at the moment, we welcome speculative applications from professionals passionate about:

Send your CV and a short introduction to:

Tell us why you’re a great fit — we’ll keep your profile on file.

Get In Touch With Us!

Whether you’re exploring partnerships, evaluating ACM technology, or seeking innovative vaccine solutions, we’d love to hear from you.

Phone

+65 6537 7364

Email

office@aavacc.com

Address

AAVACC Pte Ltd
221 Henderson Road, #07-15
Singapore 159557